|
References for Sharpen the Mind with Smart Nutrients
By George L. Redmon, PhD, ND
Vol. 3, Issue 7
Pp. 63-66
1. Bastianetto, S., Brouillette, J., Quirion, R. Neuroprotective effects of natural products: interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. Neurochem Res. 2007 April 4.
2. Inano, A., Sai, Y., Nikaido, H., et. al., Acetyl-L-canitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm. Drug Dispos. 2003 Nov; 24(8): 357-365.
3. Forman, P.J., Perez-Polo, J.R., Angelucci, L., Ramacci, MT., Taglialatela, G. Effects of acetyl-L-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) MRNA level in the central nervous system of aged rats. Prog. Neuropsychopharmacol Biol of Psychiartry. 1995 Jan; 19(1): 117-133.
4. Parihar, P.S., Brewer, G.J. Mitoenergotic failure in Alzheimer's disease. Am. J. Physiolo. Cell Physiol. 2007; 292: C8-C23.
5. Liu, J., Killile, DW., Ames, BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc. Natl. Acad. Sci USA. 2002 Feb 19; 99(4): 1876-1881.
6. Montgomery, SA., Thal, K.J., Amerin, R. Meta-analysis of double-blind randomized control clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol. 2003 March; 18(2): 61-71.
7. Szutowicz, A., Bielarczyk, H., Gul, S., Zielinski, P., Pawetczyk, T., Tamaszewicz, M. Nerve growth factor and acetyl-L-carnitine evoked shifts in acetyl-CoA and cholinergic SN56 cell vulnerability to neurotoxic imputs. J. Neurosci. Res. 2005 Jan, 1-15; 79(1-2): 185-192.
8. Acetyl-L-carnitine protects striatal neurons against invitro ischemia: the role of endogenous acetylcholine. Neuropharmacology. 2006 Jun; 50(8): 917-923.
9. Taglialatela, G., Navarra, D., Olivi, A., et. al., Neurite outgrowth in PC12 cells stimulated by acetyl-L-carnitine arginine amide. Neurochem Res. 1995 Jan; 20(1): 1-9.
10. Westland, KU., Lu, Y., Wernbach-Perez, K., et. al., Effects of nerve growth factor and acetyl-L-carnitine arginyl amide on the human neuronal line HCN-1A. Int J Dev Neurosci. 1992 Oct; 10(5): 361-373.
11. Scorziello, A., Meucci, O., Calyani, M., et. al., Acetyl-L-carnitine arginine prevents beta 25-35-induced neurotoxicity in cerebellar granule cells. Neurochem Res. 1997 March; 22(3): 256-265.
12. Packer, L., Colman, C. The Antioxidant Miracle. New York: John Wiley and Sons Inc., 1999.
13. Hagen, TM., Russell, T., Ingersoli, JL., Jiankang, L., Carol, MW., Vladimir, V., et. al., (R) - Lipoic-acid supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. The FASEB Journal. 1999; 13: 411-418.
14. Anuradha, B., Varalakshmi, P. Protective role of DL-alpha lipoic acid against mercury-induced neural lipid peroxidation. Pharmacol. Res. 1999 Jan; 39(1): 67-80.
15. Liu, J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem. Res. 2007 June 29;
16. Liu, J., Atamna, H., Kuratsune, H., Ames, B.N. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann NY Acad Sci. 2002 Apr; 959: 133-166.
17. Sinatra, S.T. The Coenzyme Q10 Phenomenon. Lincolnwood (Chicago) ILL: Keats Publishing, 1998.
18. Li, G., Zou, LY., Cao, CM., Yang, ES. Coenzyme Q10 protects SHSY5Y neuronal cells from beta amyloid toxicity and oxygen-glucose deprivation by inhibiting the opening of the mitochondrial permeability transition pore. Biofactors. 2005; 25(1-4): 97-107.
19. Moreira, PI., Santos, MS., Sena, C., Nunes, E., Seica, R. CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp. Neurol. 2005 Nov; 196(1): 112-119.
20. Young, AJ., Johnson, S., Steffens, DC., Doraiswamy, PM. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 2007 Jan; 12(1): 62-68.
21. Galpern, WR., Codkowicz, ME. Coenzyme Q treatment of neurodegenerative disease of aging. Mitochondrion. 2007 Jun; 7 Suppl: S146-S153.
22. Bliznakov, E.G. The Miracle Nutrient Coenzyme Q10. New York: Bantam Books, 1989.
23. Ramazonov, Z., Suarez, MMB. Effective Natural Stress and Weight Management Using Rhodiola Rosea and Rhododendrom Caucasicum. Sheffield MA: ATN/Safe Good Publishing, 1999.
24. Brown, RP., Gerbang, PL., Graham, B. The Rhodiola Revolution. New York: Rodale, 1995.
25. Perfumni, M., Mattioli, L. Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L extract in mice. Phytother. Res. 2007 Jan; 21(1): 37-43.
26. Shulman, RA., Dean, C. Solve It With Supplements. New York: Rodale Inc., 2007.
27. Gonzalez-Gross, M., Sola, R., Albers, U., Barrios, L., Alder, M., Castillo, MJ., et. al., B-vitamins and homocysteine in Spanish institutionalized elderly. Int J Vitam Nutr Res. 2007 Jan; 77(1): 22-23.
28. Yang, LK., Wong, KC., Wu, MY., Liao, SL., Juo, CS., Huang, RE. Correlations between folate, B-12, homocysteine levels and radiological markers of neuropathology in elderly post-stroke patients. J Am Coll Nutr. 2007 June; 26(3): 272-278.
29. Clark, R., Birks, J., Nexo, E., Ueland, P.M., Schneede, J., Scott, J., et. al., Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr. 2007 Nov; 86: 1384-1391.
30. Morris, M.C., Schneider, JA., Tangney, CC. Thoughts of B-vitamins and dementia. J Alzheimer's Dis. 2006 Aug; 9(4): 429-433.
31. Osimani, A., Berger, A., Friedman, J., Porat-Katz, BS., Abarbanel, JM. Neuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjects. J Geriatr Psychiatry Neurol. 2005 Mar; 18(1): 33-38.
32. Luchsinger, JA., Tang, MX., Miller, J., Green, R., Mayeux, R. Relation of higher folate intake to lower risk of Alzheimer's disease in the elderly. Arch Neurol. 2007 Jan; 64(1): 86-92.
33. Shiloh, R., Weizman, A., Weizer, N., Dorfman-Etrog, P., Munitz, H. Anti-depressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression preliminary open-label trial. Harefuah. 2001 May; 140(5): 369-373.
34. Cenacchi, T., Bertoldin, T., Farina, C., e. al., Cognitive decline in the elderly: a double-blind placebo-controlled multi-center study of efficacy of phosphatidylserine administration. Aging (Milano). 1993; 5: 123-133.
35. Birkmayer, G.D. Energy For Life: NADH The Energizing CoEnzyme. New York: Menuco Corporation, 1996.
36. Holford, P. Optimum Nutrition for the Mind. Laguna Beach CA: Basic Health Publications, 2004 p. 240.
37. Holmes, HC., Snodfrass, GJ., Iles, RA. Changes in the choline content of human breast milk in the first 3 weeks after birth. Eur J Pediatr. 2000 March; 159(3): 198-204.
38. Holmes-McNary, MQ., Cheng, WL., Mar, MH., Fussell, S., Zeisei, SH. Choline and choline esters in human and rat milk and in infant formulas. Am J Clin Nutr. 1996 Oct; 64(4): 572-576.
39. Smith, RC., Vroulis, G., Johnson, R., Morgan, R. Comparison on the therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacol. Bull. 1984; 20(3): 542-545.
40. Malouf, R., Birks, J. Donepezil for vascular cognitive impairment. Cochrane Database Syst. Res. 2004; (1): CD004395.
41. Amenta, F., Franch, F., Ricci, A., Yega, J.A Cholinergic neurotransmission in the hippocampus of aged rats: influence of L-alpha glycerylphosphorylcholine treatment. Ann NY Acad Sci. 1993 Sept 24; 695: 311-313.
|